Both donor and recipient CYP3A5 gene polymorphisms represent as significant factors influencing Tacrolimus weight-dose adjusted concentration in the early phase after living donor liver transplantation

Graft rejection is a primary concern after solid organ transplantation 1 .The cornerstone of graft rejection prevention lies in immunosuppressive therapy, in which Tacrolimus (Tac) plays a pivotal role in the regimen 2 .However, Tac is recognized as a medicine with narrow therapeutic range and severe toxicity 3,4 .Low Tac concentration might deprive the ability to prevent rejection while high exposure could lead to severe nephrotoxicity.Additionally, Tac has great inter-individual and intraindividual pharmacokinetic variability, especially in the